A pioneering trial of an interactive, brain-training game has unveiled a promising new frontier in the management of chronic nerve pain. Developed by a dedicated team of researchers at UNSW Sydney, the technology—known as "PainWaive"—teaches users to consciously regulate the abnormal brain activity that characterizes neuropathic pain. By offering a non-invasive, in-home alternative to traditional pharmacological interventions, this innovation provides a potential lifeline for patients who have long relied on opioids, only to face the risks of dependency and systemic side effects.

The findings, recently published in the Journal of Pain, represent a significant milestone for the NeuroRecovery Research Hub at UNSW Sydney. Led by Professor Sylvia Gustin and Dr. Negin Hesam-Shariati, the study assessed the efficacy of the PainWaive system by monitoring participants over a four-week period of interactive gameplay. The trial tracked a vast array of data points, including pain intensity and pain interference, both before and after the intervention, while utilizing electroencephalogram (EEG) headsets to record real-time shifts in brainwave patterns as the app responded to the users’ neurological feedback.

The results of this initial trial were striking. Three out of the four participants reported significant reductions in their chronic pain levels, with the most pronounced improvements occurring as they reached the final stages of the treatment program. Perhaps most notably, the level of relief achieved by these individuals was found to be comparable to, or in some cases even greater than, the relief typically provided by opioid-based medications. While these figures are encouraging, the research team remains professionally cautious, emphasizing that the small sample size and the nature of the study design require further validation.

"Restrictions in the study’s size, design and duration limit our ability to generalise the findings or rule out placebo effects," Dr. Hesam-Shariati explains. "However, the results we’ve seen are genuinely exciting. They provide our team with the necessary confidence to proceed to the next stage of development and launch a significantly larger, more comprehensive trial."

The PainWaive project is not a sudden discovery but rather the culmination of years of rigorous scientific inquiry into the mechanisms of chronic pain. It builds directly upon the seminal research of Professor Sylvia Gustin, whose work has long focused on the neurological changes within the thalamus—a central relay hub in the brain—that occur in patients suffering from neuropathic pain.

According to Professor Gustin, the brains of individuals experiencing chronic nerve pain exhibit a distinct, identifiable signature. "The brainwaves of people with neuropathic pain show a distinct pattern: more slow theta waves, fewer alpha waves, and more fast, high beta waves," she notes. "We believe these changes interfere with how the thalamus communicates with other critical regions of the brain, particularly the sensory motor cortex, which is responsible for registering pain."

Faced with this physiological reality, the research team began to ask a fundamental question: Could a treatment be developed that specifically targets and normalizes these abnormal oscillations? The result was the creation of the PainWaive interdisciplinary project, a collaboration between UNSW Science and Neuroscience Research Australia (NeuRA).

In the practical application of the trial, the four participants were provided with a comprehensive kit containing a specialized EEG headset and a tablet pre-loaded with the game application. The system was designed to be intuitive, providing users with both the technology to track their brain activity and the guidance to change it. Participants were coached on various mental strategies, such as techniques for relaxation or the practice of focusing on positive, happy memories, which helped shift their brain activity toward a more normalized state. Throughout this process, the user data was securely uploaded to the research team, allowing for remote monitoring and professional oversight.

The ease of use was a primary focus for the researchers, who aimed to move beyond the clinical setting to empower patients in their own homes. "After just a couple of Zoom sessions, participants were able to run the treatment entirely on their own," says Dr. Hesam-Shariati. "Participants felt empowered to manage their pain in their own environment. That sense of agency is a huge part of what makes this technology so special."

The journey to create a functional, affordable, and accessible piece of medical technology was not without its hurdles. Initially, the team investigated the possibility of utilizing existing commercial EEG systems to facilitate the trial. However, they quickly discovered that available options were either prohibitively expensive or lacked the technical precision required for the research. Choosing a different path, the team decided to design and build their own hardware.

"Everything except the open-source EEG board was built in-house," Dr. Hesam-Shariati explains. "And soon, even that will be replaced by a custom-designed board." By leveraging 3D printing technology, the team has managed to reduce the manufacturing cost of each headset to approximately $300. This is a dramatic decrease compared to the existing market alternatives, which often carry price tags ranging from $1,000 to as much as $20,000.

To ensure the highest quality of signal capture, the headset employs a saline-based wet electrode system that specifically targets the sensorimotor cortex. Professor Gustin emphasizes that the patient experience remained at the center of the design process. "We’ve worked closely with patients to ensure the headset is lightweight, comfortable, and user-friendly," she says. "Owning the technology offers us the potential to one day offer PainWaive as a truly affordable, accessible solution for at-home pain management, especially for those with limited access to traditional, high-cost medical treatments."

As the team prepares for the next phase of their research, they are currently calling for new participants to join two upcoming clinical trials. The first, titled the Spinal Pain Trial, will investigate the potential of this neuromodulation technology to reduce chronic spinal pain. The second, the StoPain Trial, will explore its efficacy in treating chronic neuropathic pain specifically among individuals who have suffered a spinal cord injury. By expanding the scope of their testing, the researchers hope to confirm that PainWaive can provide a reliable, sustainable, and drug-free future for those living with the debilitating effects of chronic nerve pain.